With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Delivering on the Promise of Germline Genetic Testing for RUNX1 Variants||University of Washington, Seattle / Abbye McEwen||RUNX1 Early Career Investigator Grants||2022||Washington|
|HA-1 TCR T-cell Immunotherapy for Acute Leukemia||Fred Hutchinson Cancer Research Center / Marie Bleakley, M.D., Ph.D.||Bio-Therapeutic Impact Award||2014||Washington|
|Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children||Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD||Reach Grants||2018||Washington|
|Engineering A Graft Versus Leukemia Effect into Cord Blood Transplant for Acute Lymphoblastic Leukemia||Fred Hutchinson Cancer Research Center / Rebecca Gardner||Young Investigator Grants||2011||Washington|
|Improving Development of and Patient Access to Early Phase Pediatric Cancer Clinical Trials||Seattle Children's Hospital and Regional Medical Center / Russ Geyer||Phase I/II Infrastructure Grants||2010||Washington|
|TrkB Signaling in the Genesis of Murine Neuroblastoma||University of Vermont / Rae Nishi, PhD||Innovation Grants||2007||Vermont|
|Critical Contributions of CRM1 to Leukemogenesis||University of Vermont / Jessica Linda Heath, MD||Young Investigator Grants||2015||Vermont|
|Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma||University of Virginia, School of Medicine / John Bushweller, PhD||Innovation Grants||2015||Virginia|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|
|Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma||Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP)||Innovation Grants||2015||Virginia|